¹**High-throughput detection of neutralizing antibodies to**

²**SARS-CoV-2 variants using flow cytometry**

-
- ⁴**Running Head:** High-throughput broad SARS-CoV-2 variants
- 5 neutralizing assay
- 6
- 7 Xiaohan Zhang^{1,2*}, Yajie Wang^{3*}, Mansheng Li^{1*}, Haolong Li^{4*}, Xiaomei
- 8 Zhang¹, Xingming Xu¹, Di Hu⁵, Te Liang¹, Yunping Zhu¹, Yongzhe Li^{4#},
- 9 Bingwei Wang^{2#} and Xiaobo Yu^{1,6#}
-

¹¹**Affiliations**

- 12 ¹State Key Laboratory of Medical Proteomics, Beijing Proteome 13 Research Center, National Center for Protein Sciences-Beijing ¹⁴(PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, 15 China.
- ² School of Medicine, Nanjing University of Chinese Medicine, Nanjing
- ¹⁷210023, China.
- 18 ³Department of Clinical Laboratory, Beijing Ditan Hospital, Capital
- ¹⁹Medical University, Beijing 100015, China.
- 20 ⁴ Department of Clinical Laboratory, Peking Union Medical College
- 21 Hospital, Chinese Academy of Medical Science & Peking Union
- ²²Medical College, Beijing 100730, China.

- ⁵ ProteomicsEra Medical Co., Ltd., Beijing, 102206, China
- ⁶ The First Affiliated Hospital of Wenzhou Medical University, Wenzhou,
- China.
- These authors contributed equally to this work.
- [#]Correspondence to xiaobo.yu@hotmail.com (X.Y.),
- 28 bingweiwang@njucm.edu.cn (B.W.) and yongzhelipumch@126.com (Y.
- 29 L).
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Abstract

- 67 detect broad NAbs in the population and aid in the development of
- 68 future COVID-19 vaccines and vaccination strategies.

Keywords

- 70 SARS-CoV-2, flow cytometry, neutralization, antibody, COVID-19
-
-
- -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

⁸⁹**Introduction**

⁹⁰The ongoing coronavirus 2019 (COVID-19) pandemic, caused by the 91 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 92 remains a public health concern worldwide. This is primarily attributed ⁹³to the continuous evolution of the virus and its persistent transmission 94 across global populations¹. For instance, over ten SARS-CoV-2 95 variants of concern (VOCs) have appeared, and these VOCs have the 96 potential to reduce the immune response². According to reports, 17.13% ⁹⁷(95%CI, 7.55–26.71%) of asymptomatic infected individuals may have 98 Iong-term health consequences³, which may include symptoms such ⁹⁹as fatigue, brain fog, dizziness, gastrointestinal symptoms, as well as 100 others⁴.

101 Neutralizing antibodies (NAbs) of SARS-CoV-2 are a subset of 102 antibodies that block viral entry by inhibiting the interaction between 103 the SARS-CoV-2's surface protein, Spike, and the host cell's receptor, 104 angiotensin-converting enzyme 2 (ACE2). Such NAbs can be 105 produced following COVID-19 vaccination or SARS-CoV-2 infection. 106 Identifying SAR-CoV-2 NAbs is critical for assessing vaccine efficacy, 107 evaluating individual and population immunity, monitoring variant ¹⁰⁸susceptibility, and information public health measures to control the 109 spread of COVID-19. However, traditional methods of NAb detection, 110 such those that use a live virus or a pseudovirus-based neutralization

111 assay, are slow, expensive, carry a potential risk of infection, and may

112 require specialized biosafety level 3 (BSL3) facilities $5-8$.

113 As an alternative approach, enzyme-linked immunosorbent assay ¹¹⁴(ELISA) can perform the *in vitro* neutralizing testing using purified 115 Spike, ACE2, or Spike's receptor-binding domain (RBD) that interacts 116 directly with ACE2 during viral entry. Several commercial ELISA-based 117 surrogate virus neutralization tests (sVNT) have been developed, 118 including TECO sVNT (TECO Medical) and cPASS sVNT (GenScript), ¹¹⁹which have been approved by the United States' (U.S.) Food and Drug ¹²⁰Administration (FDA) or received Conformite Europeenne (CE) 121 marking for use in the European Union $9,10$. Unfortunately, ¹²²ELISA-based methods only detect a single variant at a time, making 123 them a time-consuming option when multiple SARS-CoV-2 variants are 124 analyzed 6 .

To address this concern, Fenwick *et al.* developed a multiplexed *in-vitro* quantitative neutralization assay using Luminex technology in 2021. The assay enables the detection of NAbs targeting various Spike mutations, including D614G, D614G plus M153T, N439K, S477N, S477R, E484K, S459Y, N501T, N501Y, K417N, 60-70, P681H, Y453F, 130 and their combinations. The results obtained from this assay correlated 131 with pseudovirus neutralization (R^2 =0.65) and live virus infection (R^2 = 0.825) assays ⁷.

¹³³In a similar vein, Lynch et al. developed a multiplexed surrogate 134 virus neutralization test (plex-sVNT) for detecting NAbs to seven 135 SARS-CoV-2 variants, namely, wild type, Alpha, Beta, Gamma, Delta, 136 Kappa, and Epsilon. The results highly correlated (> 96%) with those 137 obtained from a plaque reduction neutralization test (PRNT)⁸.

138 However, it should be noted that these technologies have 139 limitations as they require access to specific Luminex and Bio-Rad 140 instruments, thereby restricting their use to specific laboratories. ¹⁴¹Moreover, some recent Omicron variants have not been accessible for 142 analysis using these methods to date¹¹.

¹⁴³In this work, we developed a high-throughput broad neutralizing ¹⁴⁴antibody (bNAb) assay that enables the systematic detection of NAbs 145 to eleven SARS-CoV-2 VOCs that is reliable, cost-effective, sensitive, 146 and used with a standard flow cytometer 12 . These variants include ¹⁴⁷D614G, Alpha, Beta, Gamma, Delta, Kappa, Omicron BA.1, Omicron ¹⁴⁸BA.2, Omicron BA.3, Omicron BA.4, and Omicron BA.5. We conducted 149 a comparative analysis of NAb detection using our SARS-CoV-2 bNAb 150 assay with commercial ELISA-based serology, U.S. FDA-approved 151 cPASS sVNT, pseudivirus-based neutralizing assays and live virus ¹⁵²based neutralization assay. Furthermore, we explored the applications 153 of the SARS-CoV-2 bNAb assay for screening therapeutic Abs, ¹⁵⁴assessing their neutralizing activity SARS-CoV-2. Finally, we analyzed

155 the broad responses of serological NAbs to SARS-CoV-2 variants in ¹⁵⁶individuals who received the third dose of either the inactivated vaccine ¹⁵⁷(Sinovac-CoronaVac) or the recombinant subunit vaccine (ZF2001) for 158 COVID-19.

159

¹⁶⁰**Results**

¹⁶¹**Schematic illustration of SARS-CoV-2 bNAb assay**

162 In the SARS-COV-2 bNAb assay, illustrated schematically in Figure 1A, the trimerized Spike proteins of six non-Omicron variants (D614G, Alpha, Beta, Kappa, Gamma, Delta) and five Omicron variants (BA.1, BA.2, BA.3, BA.4, BA.5) were expressed from human embryonic kidney 293 (HEK293) cells, purified, and coupled to the 167 magnetic-fluorescent beads, as previously reported $7,13$. During the NAbs detection process, all coupled beads were mixed together and incubated with samples containing NAbs. The NAbs bound to the 170 Spike trimer proteins, preventing their interaction with the biotinylated ACE2 receptors, which were coupled to streptavidin-phycoerythrin (SA-PE). The inhibition rate (%) was calculated as follows: Inhibition 173 rate $%$ = (1 - signal of NAb inhibition on Spike-ACE2 binding / signal 174 of Spike-ACE2 binding) \times 100%.

175 The sensitive detection of Spike-ACE2 interactions is essential for 176 assessing the presence of NAbs in clinical samples. To address this

177 requirement, we coupled the Spike protein from six SARS-CoV-2 178 variants (D614G, Alpha, Beta, Kappa, Delta, Omicron BA.1) onto 179 magnetic-fluorescent beads from Luminex and Shenzhen Wellgrow 180 Technology Co., Ltd. ("Wellgrow"), and then incubated with different 181 concentrations of ACE2. Magnetic-fluorescent beads with the 182 SARS-CoV-2 nucleocapsid (N) protein, rather than the Spike protein, 183 was employed as the negative control. The binding signals were ¹⁸⁴measured using Luminex-200 and Wellgrow flow cytometry. Notably, 185 the fluorescent signal intensity and signal to noise ratio (SNR) were 186 much higher with the Wellgrow platform than the Luminex platform 187 when ACE2 concentrations ranged from 0.01 µg/mL to 100 µg/mL ¹⁸⁸(Figure 1B, Figure S1 and Table S6).

¹⁸⁹Furthermore, we calculated the sensitivity or the lowest detection ¹⁹⁰limit (LOD) of each method, in which the LOD was equal to the signal 191 of the buffer control plus ten standard deviations (Figure 1C). The data 192 showed that the average LOD of our assay using the Wellgrow 193 platform was 35.89 ± 57.8 [-21.91~93.69]-fold higher than the Luminex 194 platform for all variants (D614G, Alpha, Beta, Kappa, Delta, Omicron 195 BA.1).

196 At last, we compared the difference of NAb titers obtained by 197 detecting the inhibition of antibody #26 to Spike-ACE2 interaction. The 198 results showed that the IC50 obtained by two platforms are highly

¹⁹⁹consistence with the r correlation of 0.9988 (Figure S1D). Therefore,

²⁰⁰we chose the Wellgrow platform as the proteomics platform for the

- 201 SARS-CoV-2 bNAb assay in this study.
-

²⁰³**Mapping Spike-ACE2 interactions of SARS-CoV-2 variants**

²⁰⁴Using our platform, we conducted a systematic investigation of the 205 interactions between ACE2 and Spike trimer proteins from eleven ²⁰⁶SARS-CoV-2 variants. This was achieved by incubating a bead array 207 with different concentrations of ACE2 (Figure 2). The results 208 demonstrated that the fluorescent signals from the Spike trimer 209 proteins increased with increasing concentrations of ACE2, indicating 210 the formation of Spike-ACE2 complexes on the beads (Figure 2A).

211 Spike mutations were found to influence the interaction dynamics. ²¹²At the maximal concentration of 10 µg/mL ACE2, Alpha and Delta 213 variants exhibited the highest signals, followed by Beta, BA.4, BA.5, ²¹⁴D614G, Gamma, BA.1, BA.2, and Kappa, with BA.3 showing the 215 lowest signal. In contrast, the N protein, used as a negative control, 216 consistently displayed the lowest signal regardless of ACE2 217 concentration.

218 To further assess the binding affinity, we calculated the 219 half-maximal effective concentration (EC50) using the standard curve 220 for each SARS-CoV-2 variant (Figure 2B). The results showed that

239 In addition, to demonstrate the specificity of our assay, we tested 240 the binding ability of ACE2 to the Spike proteins from MERS, 241 SARS-CoV and six SARS-CoV-2 variants. The results showed that the 242 binding signal of ACE2 to six SARS-CoV-2 variant Spike proteins was

249

²⁵⁰**Comparison of SARS-CoV-2 bNAb assay to ELISA**,**cPass sVNT,**

²⁵¹**pseudovirus-based neutralization and live virus based** ²⁵²**neutralization assays.**

253 To assess the reliability of the SARS-CoV-2 bNAb assay, we compared 254 the SARS-CoV-2 bNAb assay to an ELISA that was used to detect 255 anti-Spike IgG antibodies¹⁷. The results showed a high correlation 256 between the levels of D614G NAbs detected using our SARS-CoV-2 257 bNAb assay and the anti-Spike IgG antibodies obtained by the ELISA 258 $[R = 0.89, p-value (p) < 2.2 e-16]$ in a cohort of 75 individuals (Figure 259 3A).

260 Next, we compared the NAb results obtained from the 261 SARS-CoV-2 bNAb assay to those obtained from the FDA-approved 262 cPass sVNT test 6.9 . The data obtained using the SARS-CoV-2 bNAb 263 assay and cPass sVNT test demonstrated a higher correlation to each 264 other $(R = 0.93, p < 2.2 e-16)$ compared to the assay using Luminex

273 Additionally, we compared the inhibition rate (%) of NAbs obtained ²⁷⁴by SARS-CoV-2 bNAb assay to the NAb titers obtained by 275 pseudovirus-based neutralization assay or live virus based 276 neutralization assay. For 10 serum samples from mice administered 277 with WT mRNA vaccines, a high correlation was found between D614G 278 NAbs inhibition rate (%) detected using SARS-CoV-2 bNAb assay and 279 WT NAb titers by pseudovirus-based neutralization assay ($R = 0.96$, p 280 \leq 0.0001) and live virus based neutralization assay (R = 0.79, p \leq ²⁸¹0.0001) (Figures 3C, 3E). Similarly, for 10 serum samples from mice 282 administered with BA.1 mRNA vaccines, notable correlations were 283 observed between the levels of BA.1 NAbs detected using 284 SARS-CoV-2 bNAb assay and pseudovirus-based neutralization ($R =$ 285 0.66, $p = 0.0017$) and live virus based neutralization assays (R = 0.64, 286 $p = 0.0022$) (Figures 3D, 3F). Then, we compared the inhibition rate (%)

287 of NAbs obtained by SARS-CoV-2 bNAb assay and the NAb titers 288 obtained by pseudovirus-based neutralization assay in the serum of ²⁸⁹135 individuals with second dose vaccination. We detected serum ²⁹⁰NAbs against the D614G variant using both assays. The results 291 showed a correlation coefficient (r) of 0.65, demonstrating the 292 consistency between the results obtained through inhibition and those 293 obtained with NAb titers (Figure S4 and Table S7).

294

²⁹⁵**Identification of broadly neutralizing monoclonal/polyclonal Abs**

²⁹⁶**against SARS-CoV-2 variants**

²⁹⁷To demonstrate the application of SARS-CoV-2 bNAb assay in 298 identifying monoclonal/polyclonal NAbs for potential treatment 299 purposes, we tested six anti-Spike antibodies that are available in the 300 laboratory²⁰ (Figure 4A). The results revealed that three antibodies ³⁰¹(#26, #20, #21) have neutralizing activity. Antibodies #20 and #21 ³⁰²inhibited ACE2 binding to D614G, Alpha, Beta, Kappa and Delta 303 variants, but were not effective in inhibiting the ACE2 binding to the ³⁰⁴Omicron BA.1 variant. Antibody #26 exhibited the ability to inhibit ³⁰⁵Spike-ACE2 interactions for D614G, Alpha, Beta, Kappa,Delta and 306 Omicron BA.1 variants.

³⁰⁷Subsequently, the half-maximal inhibitory concentration (IC50) 308 values were calculated and represented in a heatmap (Figure 4B). The

331 indicating the resistance of these variants to the Sinovac-CoronaVac

332 vaccine and the ZF2001 vaccine (Figure 5A).

341 SARS-CoV-2 bNAb assay, we detected the serum from the individuals 342 before vaccination (n = 147) and after three-dose vaccination (n = 56). ³⁴³The results showed that the serum NAb levels were significantly higher 344 in the vaccination group than un-vaccination group ($p < 0.0001$) (Figure 345 S3), indicating our SARS-CoV-2 bNAb assay is highly specific for the 346 detection of serum NAbs.

347

³⁴⁸**Discussion**

³⁴⁹Even though the World Health Organization has announced that 350 COVID-19 is no longer a public health emergency of international 351 concern, the genome sequence of SARS-CoV-2 is continually evolving ³⁵²and the new variants (i.e. EG.5) may has the potential to escape the

immunity and threat the people's health, especially among 354 immunocompromised individuals 23,24 . Therefore, there is still a need for effective COVID-19 vaccines to prevent and control viral transmission. The development and deployment of vaccines for COVID-19, as well as the evaluation of population immunity, remain important for public 358 health²⁵.

359 In this work, we developed a high-throughput SARS-CoV-2 bNAb ³⁶⁰assay to detect a wide range of NAbs to non-Omicron and Omicron 361 variants. Compared to the assay using Luminex technology^{$\frac{8}{3}$}, our 362 SARS-CoV-2 bNAb assay is 35-fold more sensitive, 2.5-fold less costly, ³⁶³and can be accessible to any laboratory that has a standard flow 364 cytometer with the 532 nm and 635 nm lasers. Moreover, the ³⁶⁵simultaneous detection of NAbs to multiple SARS-CoV-2 variants can ³⁶⁶be achieved within a single experiment, and the assay can be 367 periodically updated to include new variants. The reliability of NAb 368 detection using our SARS-CoV-2 bNAb assay is demonstrated through 369 comparisons with ELISA-based IgG serology, the cPass sVNT assay, 370 pseudovirus-based neutralization assay and live virus based 371 neutralization assay (Figure 3).

372 Using this platform, we constructed a comprehensive landscape of 373 Spike trimer and ACE2 interactions for eleven SARS-CoV-2 variants ³⁷⁴(Figure 2). The results provide evidence that Omicron BA.1 showed the

375 strongest binding affinity to the ACE2 receptor 26.27 . Notably, the 376 transmission rate of SARS-CoV-2 and its variants is dependent on 377 numerous factors, including immune resistance, toxicity, etc^{28} .

378 Furthermore, our investigation of serum NAbs in vaccinated 379 individuals showed that the third dose of the inactivated vaccine or 380 recombinant RBD vaccine resulted in a strong inhibition of Spike-ACE2 381 interactions to the non-Omicron variants (D614G, Alpha, Beta, Gamma, ³⁸²Kappa). However, the protection was significantly decreased for ³⁸³Omicron variants (BA.2, BA.1, BA.3, BA.5, BA.4) (Figure 5). These 384 results demonstrate the significance of our proteomics platform in 385 evaluating the broad protective activity of COVID-19 vaccines, which 386 can guide the development of COVID-19 vaccines.

387 It is important to acknowledge some limitations of our study. First, ³⁸⁸the *in vitro* detection of NAbs may not represent viral neutralization *in* ³⁸⁹*vivo*, although previously reported evidence has shown a good 390 correlation between NAbs detected *in vitro* and *vivo*⁵⁻⁸. Second, the 391 relationship between the inhibition levels obtained with the ³⁹²SARS-CoV-2 bNAb assay and the SARS-CoV-2 infection remains 393 unclear. Third, the number of clinical samples employed in this study ³⁹⁴was limited, and the assay should be executed in a larger cohort to 395 determine the NAb levels induced by different vaccines and infection 396 with SARS-CoV-2 variants. Finally, the SARS-CoV-2 wild-type was not

403

⁴⁰⁴**Conclusion**

⁴⁰⁵We have successfully developed and validated a high-throughput 406 proteomics platform, enabling the comprehensive evaluation of NAbs 407 against a wide range of SARS-CoV-2 variants. This platform offers an 408 efficient, sensitive, and cost-effective approach for detecting broad ⁴⁰⁹NAbs within the population, providing an opportunity to guide the 410 design and evaluation of vaccines with enhanced protective efficacy 411 against evolving SARS-CoV-2 strains. Overall, our work contributes to 412 the ongoing efforts in combating the COVID-19 pandemic and 413 advancing our understanding of immune responses to SARS-CoV-2.

⁴¹⁵**References**

416 1. The E. The COVID-19 pandemic in 2023: far from over. Lancet. 2023;401(10371):79.
417 2. Khoury DS, Docken SS, Subbarao K, et al. Predicting the efficacy of variant-modified
6. COVID-19 vaccine boosters. Nat Med. 202 418 COVID-19 vaccine boosters. *Nat Med.* 2023;29(3):574-578.
419 3. Ma Y, Deng J, Liu Q, et al. Long-Term Consequences of Asymptomatic SARS-CoV-2
1420 Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res P* 419 3. Ma Y, Deng J, Liu Q, et al. Long-Term Consequences of As
420 Infection: A Systematic Review and Meta-Analysis. *Int J El*
421 2023;20(2).
19 420 Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*.
421 2023;20(2).
19 421 Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health.*
421 2023;20(2). $\frac{2(2-2)(2)}{2}$

⁵⁰⁸**Contributions**

⁵¹³**Acknowledgment**

512

514 This work was supported by the Beijing Municipal Natural Science 515 Foundation (M23010 and L234034), National Key R&D Program of ⁵¹⁶China(2022YFE0210400, 2021YFA1301604, 2020YFE0202200), 517 State Key Laboratory of Proteomics (SKLP-O202007), Academic 518 leader of high-level public health technical personnel construction 519 project of Beijing Municipal Health Commission (2022-2-014), 520 Guangdong Province Science and Technology Planning Project ⁵²¹(2020B1111100006), Innovation Team and Talents Cultivation Program 522 of National Administration of Traditional Chinese Medicine. (No: 523 ZYYCXTD-C-202204). We would like to thank the bioinformatics 524 platform of the National Center for Protein Sciences (Beijing) for their 525 support in the data analysis of this project. We also thank Dr. Brianne 526 Petritis for her critical review and editing of this manuscript.

⁵²⁸**Declaration of Interest Statement**

529 The authors have declared no conflict of interest.

⁵³¹**Supplementary materials**

- 532 This article contains Supplementary Figure 1-4 and Supplementary
- 533 Table1-7.
- 534

⁵³⁵**Tables**

536 Table 1. Clinical serum samples employed in this study

537

⁵³⁸**Figure legends**

⁵⁴³NAbs, the beads coupled with SARS-CoV-2 variants Spike trimer ⁵⁴⁴proteins are incubated with NAbs. The NAbs with neutralizing activity ⁵⁴⁵will block the Spike interaction with biotinylated ACE2 and SA-PE. The 546 signal intensities of the Spike trimer-ACE2 interaction are inversely 547 proportional to the level of NAbs. During the NAbs detection process, 548 all coupled beads were mixed together and incubated with samples 549 containing NAbs. The NAbs bound to the Spike trimer proteins, 550 preventing their interaction with the biotinylated ACE2 receptors, which 551 were coupled to streptavidin-phycoerythrin (SA-PE). (B) Dose 552 relationship curve of Spike-ACE2 interactions using Wellgrow and ⁵⁵³Luminex platforms. MFI = mean fluorescence intensity. (C) A 554 comparison of the sensitivity to detect Spike-ACE2 interactions with the ⁵⁵⁵Wellgrow and Luminex platforms.

Figure 2. Spike trimer-ACE2 interactions across different SARS-CoV-2 variants and ACE2 concentrations. (A) Dose 559 relationship curve of the interactions between ACE2 and six SARS-CoV-2 non-Omicron variants and five Omicron variants The x-axis represents the concentrations of the host ACE2 receptor. The 562 y-axis represents the median of fluorescent signal intensity (MFI) of the 563 SARS-CoV-2 Spike trimer-ACE2 interaction. N = nucleocapsid protein, which was used as a negative control. (B) Distribution of the NAb

⁵⁷⁴**Figure 3. Comparison of SARS-CoV-2 bNAb assay to ELISA**, ⁵⁷⁵**cPass sVNT, pseudovirus-based neutralization and live virus** ⁵⁷⁶**based neutralization assays.** (A) Correlation analysis of serological 577 IgG detection between the SARS-CoV-2 bNAb assay and an ⁵⁷⁸ELISA-based IgG serology. (B) Correlation analysis of NAb detection 579 using the SARS-CoV-2 bNAb assay and the FDA-approved cPass 580 sVNT test. The concordance of NAb detection using the ELISA and 581 sVNT assays was calculated as the positive and negative percent 582 agreement (PPA and NPA, respectively). The blue and red dots 583 represent positive (neutralizing activity) and negative (non-neutralizing) 584 cases as determined by the comparative analysis, respectively. (C) ⁵⁸⁵Correlation analysis of D614G NAbs inhibition rate (%) from the 586 SARS-CoV-2 bNAb assay with WT NAb titers from pseudovirus-based

Figure 4. Identification of monoclonal/polyclonal Abs with broad neutralizing capability. (A) Dose relationship curve demonstrating the 598 ability of the NAb to inhibit SARS-CoV-2 variant Spike trimer-ACE2 interactions. The x-axis represents the concentrations of the NAb. The 600 y-axis represents the percent activity $(\%)$ of the NAb. N = nucleocapsid 601 protein, which was used as a negative control. (B) Heatmap showing 602 the IC50 of NAbs against different SARS-CoV-2 variants. The detail of 603 monoclonal/polyclonal Abs are provided in Table S5.

Figure 5. Detection of serum NAbs in vaccinated individuals. (A) Boxplot showing the distribution of inhibition rate (%) of serum NAbs against SARS-CoV-2 variants in 56 vaccinated individuals. (B) Comparison of NAbs produced between groups receiving the

Preparation of SARS-CoV-2 bNAb reagents

626 The SARS-CoV-2 bNAb assay was developed in ProteomicsEra Medical Co., Ltd (Beijing, China). Briefly, 3 μg SARS-CoV-2 Spike 628 trimer proteins (Sino Biological., Novoprotein and ACROBiosystems; 629 China) (Table S1) were coupled to 1×10^6 magnetic-fluorescent beads 630 (Wellgrow Technology Co., Ltd.) as previously described³². First, 12

631 differently encoded magnetic-fluorescent beads, numbered 102-108 632 and 201-205 (Table S2), were chosen. Then 125 μ L containing 633 1 \times 10⁶ beads were washed with 100 μL ddH2O and activated with 80 634 μL of "activation buffer" (50 mM 2-(N-morpholino) ethanesulfonic acid ⁶³⁵(MES) pH 5.0) (Sigma-Aldrich, St. Louis, MO). Then the activated 636 beads were mixed with 10 μ L of 50 mg/mL sulfo-N-hydroxysuccinimide ⁶³⁷(NHS) (Thermo Scientific, USA) and 10 μL of 50 mg/mL ⁶³⁸1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC) ⁶³⁹(Solarbio, Beijing, China). After incubation for 20 min at room 640 temperature with gentle mixing, the beads were washed twice with 250 641 μL "coupling buffer" (50 mM MES pH 5.0) and resuspended in 200 μ^L 642 coupling buffer. Then 3 μ g of Spike trimer proteins were added to the ⁶⁴³bead solution and incubated for 2 h at room temperature. After washing, ⁶⁴⁴the beads underwent blocking with "blocking buffer" (PBST-B, PBS pH ⁶⁴⁵7.4, 0.05% Tween-20, 1% BSA), and the coupled beads were 646 subsequently stored at 2-8 °C in "storage buffer" (PBST-BN, PBS pH ⁶⁴⁷7.4, 0.05% Tween-20, 0.1% BSA, 0.05% NaN3).

⁶⁴⁹**Detection of Spike-ACE2 interactions using SARS-CoV-2 bNAb** ⁶⁵⁰**assay** ⁶⁵¹First, a 50 μL mixed solution containing 12 different SARS-CoV-2 Spike

652 trimer protein-coupled beads (2500 beads per type) (Table S3) was

⁶⁸⁶**Detection of Serum NAbs using SARS-CoV-2 bNAb assay.**

⁶⁸⁷First, a 50 μL mixed solution containing 12 different SARS-CoV-2 Spike 688 trimer protein-coupled beads (2500 beads per type) (Table S2) was 689 added to each well of a 96-well plate, followed by 50 μ L of the serum 690 samples which were diluted to 1:20 with PBST-B. After incubation for 2 691 h at room temperature on a shaker, the beads were washed with 692 PBST-B three times. Then the beads were incubated with 50 μ L 693 biotinylated ACE2 (0.5 μ g/mL) for 1 hour at room temperature. After ⁶⁹⁴washing, the binding of ACE2 to Spike trimer proteins were detected 695 using 50 μ L SA-PE (2 μ g/mL) and incubated the mixture for 30 minutes 696 at room temperature. Finally, after washing with PBST-B twice, the

beads were resuspended in a 200 μL PBST-B solution. The fluorescent signal was then detected at 200 beads/region using the EasyCell flow cytometry (Wellgrow Technology Co., Ltd.) with excitation wavelengths 700 of 532 nm and 635 nm.

701

⁷⁰²**Detection of Serum NAbs using the anti-Spike RBD IgG antibodies**

⁷⁰³**obtained by the ELISA.**

 704 The assay was conducted as described previously¹⁷. A capture 705 sandwich ELISA detection kit (PROPRIUM, Hangzhou, China) was 706 used to detect SARS-CoV-2 antibodies against the Spike protein RBD. ⁷⁰⁷The SARS-CoV-2 Spike RBD protein was pre-coated onto the solid 708 phase, allowing it to form an antigen-antibody complex with IgG ⁷⁰⁹anti-RBD antibodies from 100 μL of diluted serum samples (1:30 710 dilution ratio) or standards. After washing, HRP-conjugated anti-human 711 IgG was added to form an antigen-antibody-HRP complex. The 712 substrate solution TMB was then introduced, and the resulting color 713 intensity was proportional to the level of SARS-CoV-2-neutralizing 714 antibodies. The optical density (OD) at 450 nm was measured, and a 715 threshold of 10 BAU/ml was used to determine sero-positive and 716 negative samples for anti-Spike RBD IgG.

718 Detection of Serum NAbs using cPassTM sVNT Kit.

The assay was conducted as described previously¹⁷. Using competitive ⁷²⁰ELISA, the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) 721 assay (Genscript, Nanjing, China) identified neutralizing antibodies ⁷²²present in the bloodstream that obstruct the interaction between the 723 viral Spike glycoprotein receptor-binding domain (RBD) and human ⁷²⁴ACE2. Following the manufacturer's instructions, diluted serum 725 samples (1:10 dilution ratio) and controls were pre-incubated at 37 \Box for ⁷²⁶15 minutes to allow binding of neutralizing antibodies (NAb) and ⁷²⁷HRP-RBD (antigen derived from SARS-CoV-2 variant D614G), using a ⁷²⁸1:1 volume ratio. Subsequently, the mixture was transferred to a 729 capture plate, pre-coated with hACE2 protein, where NAb-unbound ⁷³⁰HRP-RBD was captured on the plate, while NAb-bound HRP-RBD 731 remained in the supernatant and was washed away. Next, 100 μ L of 732 TMB and 50 μ L of stop solution were added, and the plate was read at ⁷³³450 nm. The sample's absorbance was inversely correlated with the 734 titers of anti-SARS-CoV-2-neutralizing antibodies. To ensure result 735 validity, the OD450 values of positive controls (> 1.0) and negative 736 controls (< 0.3) had to fall within specific ranges. An inhibition rate of \ge ⁷³⁷30% was considered positive for SARS-CoV-2-neutralizing antibody ⁷³⁸determination. The inhibition rate was calculated as follows: 739 Inhibition□=□(1 - OD value of sample/OD value of negative 740 control)⊡×⊟100%.

741

⁷⁴²**Pseudovirus-based neutralization assay.**

⁷⁴³The SARS-CoV-2 pseudovirus was prepared using the VSV-Δ^G 744 system in which the glycoprotein (G) gene was replaced with the firefly 745 Iuciferase (Fluc) reporter gene $33,34$. The S protein was overexpressed 746 and displayed on the VSV pseudovirus. Following S-ACE2 interaction, 747 the pseudovirus entered the host cell where the Fluc gene was 748 transcribed and translated. The addition of luciferase substrate 749 resulted in luminescence where the amount of luminescence is ⁷⁵⁰proportional to the level of pseudoviral entry. The preparation process 751 of SARS-CoV-2 pseudovirus begins with the cloning of the S gene 752 encoding the S protein of the virus. Subsequently, this gene is inserted 753 into a modified VSV backbone, replacing the original G gene. The ⁷⁵⁴resulting construct, containing the S protein gene in lieu of the G gene 755 and complemented by the Fluc reporter gene, forms the foundation of 756 the pseudovirus. The pseudovirus equipped with the S protein can 757 interact with the ACE2 receptor on the surface of host cells, thereby ⁷⁵⁸facilitating the entry of the pseudovirus into the cells. Once inside the 759 cells, the Fluc gene will be transcribed and translated to produce 760 luciferase.

761 The assay was conducted following previously described 762 methods^{20,35}. Huh7 cells were seeded at a concentration of 2 \times 10⁴

Live virus based neutralization assay.

778 The assay was conducted as described previously³⁵. To assess the 779 SARS-CoV-2-specific NAb titer in serum, we employed a cytopathic 780 effect (CPE)-based microneutralization assay, utilizing the 781 SARS-CoV-2 virus strain BetaCoV/Beijing/IME-BJ01/2020 (Accession 782 No. GWHACAX01000000) and Vero cells (ATCC, CCL81). Serum 783 samples underwent heat inactivation for 30 minutes at 56 \degree C and were 784 subsequently two-fold serially diluted (ranging from 1:4 to 1:2048)

785 using Dulbecco's Modified Eagle Medium (DMEM) from Thermo Fisher 786 Scientific. These dilutions were then mixed with an equivalent volume 787 of the virus solution to achieve a 50% tissue culture infectious dose ⁷⁸⁸(TCID50) of 100 in each well.

789 The serum-virus mixtures were incubated for 1 hour at 37 \degree C to 790 allow for sufficient neutralization reactions to occur. Following 791 incubation, the mixtures were gently added to 96-well plates containing 792 semi-confluent Vero cells with a density exceeding 80%. The plates 793 were then incubated for a further 3 days at 37 \degree C to allow for the 794 development of cytopathic effects (CPEs) on the Vero cells. Using an 795 inverted microscope, the CPEs on the Vero cells were carefully 796 observed and recorded. The neutralizing titer was determined as the 797 reciprocal of the highest sample dilution that successfully protected at ⁷⁹⁸least 50% of the cells from CPE. In cases where no neutralization 799 reaction was observable even at the initial serum dilution of 1:4, an 800 arbitrary titer of 2 (half of the limit of quantification) was assigned.

801

⁸⁰²**Data analysis**

⁸⁰³To compare the inhibition rate (%) of serum NAbs against the D614G 804 variant and other SARS-CoV-2 variants, the raw inhibition rates of ⁸⁰⁵different variants were first normalized using minimum-maximum 806 normalization. Statistical analyses were performed using Student's

B

A